2019-11-13T16:28:50-06:00 2018-12-31 043077056 MOODY FAMIGLIETTI & ANDRONICO LLP 1 HIGHWOOD DRIVE TEWKSBURY MA 01876 990 2018-01-01 463250612 EVIDENCE FOR HEALTHCARE IMPROVEMENT EVID 6175284013 TWO LIBERTY SQUARE NINTH FLOOR BOSTON MA 02109 SARAH EMOND CHIEF OPERATING OFFICER 6175284013 2019-11-13 MATTHEW KALIL CPA MBA P01517069 9785575300 2019-11-13 64.27.39.203 2019-11-13 09:45:51 ES P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 4141E4A5C25AD619B9DECADFBF31C872A80AFA19 2018 2020-04-17 16:48:07Z INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW STEVEN D PEARSON MD TWO LIBERTY SQUARE NINTH FLOOR BOSTON MA 02109 2104041 0 X ICER-REVIEW.ORG X 2013 CA SEE SCHEDULE O 10 10 35 0 0 29468 14466611 1124458 1092285 972936 1247 3428 0 3219 15560143 2104041 0 0 0 0 2970647 3696729 0 0 62587 2234949 2604255 5205596 6300984 10354547 -4196943 14128547 9910517 1102141 1081054 13026406 8829463 X FAIR PRICING, FAIR PATIENT ACCESS, AND FUTURE INNOVATION. 0 0 1364670 THE MIDWEST COMPARATIVE EFFECTIVENESS PUBLIC ADVISORY COUNCIL (MIDWEST CEPAC), A CORE PROGRAM OF THE INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW (ICER), IS A NATIONALLY-RECOGNIZED COMMUNITY FORUM. THE MIDWEST CEPAC CONVENES MULTIPLE TIMES EACH YEAR AT PUBLIC MEETINGS TO APPRAISEOBJECTIVE EVIDENCE REPORTS, TAKE PUBLIC VOTES ON THE CLINICAL AND ECONOMIC VALUE OF HEALTH CARE INTERVENTIONS, AND DEVELOP RECOMMENDATIONS FOR HOW STAKEHOLDERS CAN APPLY EVIDENCE TO IMPROVE THE QUALITY AND VALUE OF HEALTH CARE. 1361674 THE NEW ENGLAND COMPARATIVE EFFECTIVENESS PUBLIC ADVISORY COUNCIL (NEW ENGLAND CEPAC), A CORE PROGRAM OF THE INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW (ICER), IS A NATIONALLY-RECOGNIZED COMMUNITY FORUM. THE NEW ENGLAND CEPAC CONVENES MULTIPLE TIMES EACH YEAR AT PUBLIC MEETINGS TO APPRAISE OBJECTIVE EVIDENCE REPORTS, TAKE PUBLIC VOTES ON THE CLINICAL AND ECONOMIC VALUE OF HEALTH CARE INTERVENTIONS, AND DEVELOP RECOMMENDATIONS FOR HOW STAKEHOLDERS CAN APPLY EVIDENCE TO IMPROVE THE QUALITY AND VALUE OF HEALTH CARE. 1079332 THE CALIFORNIA TECHNOLOGY ASSESSMENT FORUM (CTAF), A CORE PROGRAM OF THE INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW (ICER), IS A NATIONALLY-RECOGNIZED COMMUNITY FORUM. THE CALIFORNIA TECHNOLOGY ASSESSMENT FORUM CONVENES MULTIPLE TIMES EACH YEAR AT PUBLIC MEETINGS TO APPRAISE OBJECTIVE EVIDENCE REPORTS, TAKE PUBLIC VOTES ON THE CLINICAL AND ECONOMIC VALUE OF HEALTH CARE INTERVENTIONS, AND DEVELOP RECOMMENDATIONS FOR HOW STAKEHOLDERS CAN APPLY EVIDENCE TO IMPROVE THE QUALITY AND VALUE OF HEALTH CARE. 832003 NEW DRUG ASSESSMENT PROGRAM: ICER'S PROGRAM TO EVALUATE NEW DRUGS AT OR NEAR THE TIME OF FDA APPROVAL PROVIDES AN INDEPENDENT ANALYSIS OF THE COMPARATIVE EFFECTIVENESS OF NEW DRUGS, ALONG WITH AN ASSOCIATED "VALUE-BASED PRICE BENCHMARK," WITH THE OBJECTIVE OF HELPING DECISION-MAKERS UNDERSTAND AND APPLY EVIDENCE TO IMPROVE VALUE THROUGHOUT THE HEALTH CARE SYSTEM. THE REPORTS OF THE NEW DRUG ASSESSMENT PROGRAM ARE VETTED THROUGH A PUBLIC PROCESS AND ITERATIVE ENGAGEMENT WITH PATIENTS, CAREGIVERS, AND CLINICAL EXPERTS. 776144 939999 MEMBERSHIP: THE ICER MEMBERSHIP PROGRAM LAUNCHED IN 2015 TO GIVE A SELECT NUMBER OF LEADING HEALTH CARE ORGANIZATIONS A UNIQUE OPPORTUNITY TO SHAPE THE FUTURE OF EVIDENCE AND COVERAGE POLICY IN THE U.S. THE TENSION BETWEEN INNOVATION AND HEALTH CARE COSTS CONTINUES TO FOCUSCRITICAL ATTENTION ON HOW EVIDENCE WILL BE DEVELOPED BY MANUFACTURERS AND HOW IT WILL BE INTERPRETED BY PAYERS IN MAKING COVERAGE DECISIONS. BENEFITING FROM ICER'S EXPERIENCE AS A LEADER IN HEALTH TECHNOLOGY ASSESSMENT, AND ITS UNIQUE ABILITY TO SERVE AS AN ENGAGED, OBJECTIVECONVENER AND MODERATOR, ICER MEMBERSHIP BRINGS TOGETHER A SMALL, INFLUENTIAL GROUP OF EVIDENCE LEADERS FROM PUBLIC AND PRIVATE PAYER ORGANIZATIONS, HEALTH TECHNOLOGY ASSESSMENT GROUPS, AND LIFE SCIENCE COMPANIES TO ADDRESS KEY CONTROVERSIES IN EVIDENCE METHODS AND POLICY. WORKING TOGETHER IN A BALANCED, NON-ADVERSARIAL ENVIRONMENT, ICER MEMBERS GAIN THE SKILLS AND INSIGHTS IN EVIDENCE POLICY NECESSARY TO STRENGTHEN THEIR COMPETITIVE POSITION IN THE MARKETPLACE. 32937 OTHER ACTIVITIES INCLUDING SPEAKING FEES AND SMALL POLICY PROJECTS. 1608147 972936 5413823 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 71 0 1 35 1 0 0 0 0 0 0 0 0 0 0 0 0 X 10 10 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA MA X THE ORGANIZATION 6175284013 TWO LIBERTY SQUARE NINTH FLOOR BOSTON MA 02109 MARK SKINNER DIRECTOR 1.00 X 0 0 0 LEWIS SANDY DIRECTOR 1.00 X 0 0 0 ANYA RADER WALLACK DIRECTOR 1.00 X 0 0 0 CARMELLA BOCCHINO RN MBA DIRECTOR 1.00 X 0 0 0 WENDY EVERETT SCD DIRECTOR 1.00 X 0 0 0 RON POLLACK JD DIRECTOR 1.00 X 0 0 0 TANISHA CARINO DIRECTOR 1.00 X 0 0 0 FRANCES VISCO DIRECTOR 1.00 X 0 0 0 ELLEN ANDREWS DIRECTOR 1.00 X 0 0 0 MURRAY ROSS PHD CHAIR 1.00 X X 0 0 0 STEVEN D PEARSON PRESIDENT 50.00 X 476398 0 48993 SARAH K EMOND TREASURER, SECRETARY, COO 50.00 X 194532 0 36323 DAN OLLENDORF CHIEF SCIENTIFIC OFFICER 50.00 X 159484 0 36808 DAVID RIND CHIEF MEDICAL OFFICER 50.00 X 234494 0 46503 DAVID WHITRAP VP OF COMM. & OUTREACH 50.00 X 191901 0 29877 RICHARD CHAPMAN DIR OF HEALTH ECONOMICS 50.00 X 201206 0 12335 WILLIAM DREITLEIN DIR OF PHARMACEUTICAL INTELLIGENCE 50.00 X 146614 0 25743 ALEXANDRA ELLIS SENIOR SCIENTIST, HTA 50.00 X 137782 0 12017 VARUN KUMAR ASSOC DIR OF HEALTH ECONOMICS 50.00 X 111270 0 18481 ANITA CHAN FINANCE DIRECTOR 50.00 X 103489 0 5810 1957170 0 272890 10 0 1 0 UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVE NE SEATTLE WA 98198 RESEARCH 310576 REGENTS OF THE U OF CA 3333 CALIFORNIA STREET STE 315 SAN FRANCISCO CA 94143 RESEARCH 210000 UNIVERSITY OF COLORADO 12850 E MONTVIEW BLVD C238 AURORA CA 80045 RESEARCH 106250 REINER BANKEN 125 RUE SAINT-NORBERT MONTREAL HX G QUEBEC CA RESEARCH 104000 4 1124458 1124458 MEMBERSHIP DUES 900099 939999 939999 CONTRACT SERVICE REVEN 541700 32937 32937 972936 3428 3428 OTHER INCOME 900099 3219 3219 3219 2104041 972936 0 6647 X 1455313 1324380 100502 30431 1780185 1470544 284660 24981 71601 56588 14563 450 180868 153510 27210 148 208762 180104 25624 3034 15661 15661 18010 18010 1607208 1484226 122240 742 45010 19485 25303 222 40844 23927 16729 188 254669 249374 2904 2391 285493 273719 11774 183950 176364 7586 110950 110950 BOARD COSTS 22478 22478 PROFESSIONAL DEVELOP. 19982 1602 18380 6300984 5413823 824574 62587 422241 127525 1290863 1837303 11784111 7443707 47262 30000 31274 52951 535717 237974 379843 297743 172953 121288 14128547 9910517 297703 270443 494999 545000 309439 265611 1102141 1081054 X 1084154 1406729 11942252 7422734 13026406 8829463 14128547 9910517 -4196943 0 X X 0 1 X 1 0 X 2037603 5481696 286234 14466611 1124458 23396602 2037603 5481696 286234 14466611 1124458 23396602 19549740 3846862 121 1381 1247 3428 6177 3219 3219 23405998 4541168 0.16440 X IN 2014 (THE ORGANIZATION'S FIRST FULL YEAR AS AN INDEPENDENT NON-PROFIT), THE ISSUE OF HIGH DRUG PRICES HIT THE NATIONAL STAGE WITH THE APPROVAL OF NEW CURES FOR HEPATITIS C PRICED AT $1,000 PER PILL. AROUND THE SAME TIME, THE ORGANIZATION WAS FINE-TUNING ITS METHODOLOGY TO DETERMINE FAIR PRICES FOR PRESCRIPTION DURGS. THE PUBLIC'S NEED FOR INDEPENDENT ANALYSES OF FAIR DRUG PRICES CAUSED THE ORGANIZATION TO GROW AT A FAST PACE THAN IT WAS ABLE TO CULTIVATE NEW DONORS TO SUPPORT THE WORK, MEANING IT RELIED ON A FEW SELECT DONORS TO SUPPORT THE SCALING OF THE ORGANIZATION. THE ORGANIZATION HAS BEEN BUILDING ITS INFRASTRUCTURE AROUND THE PUBLIC NEED, NOT AROUND DONORS, WHICH HAS MEANT THE ORGANIZATION FAILED THE 33 1/3% TEST THIS YEAR. LATE IN 2018, THE ORGANIZATION HIRED A FUNDRAISING PROFESSIONAL TO BE SINGULARLY FOCUSED ON INCREASING THE NUMBER OF DONORS FROM THE GENERAL PUBLIC, AND THE ORGANIZATION IS HAVING EARLY SUCCESS WITH THOSE EFFORTS. THE ORGANIZATION ALSO RECENTLY ADDED A "DONATE" BUTTON TO ITS WEBSITE TO ENCOURAGE PUBLIC SUPPORT FOR ITS MISSION. THE GOVERNANACE BOARD OF THE ORGANIZATION IS ALSO FOCUSED ON SUPPORTING THE PUBLIC'S INTEREST, AS WE HAVE THE PATIENT, CONSUMER, PROVIDER, AND PAYER PERSPECTIVES REPRESENTED ON THE BOARD, ADVISING ON THE ORGANIZATION'S STRATEGIC PRIORITIES. SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: CREDIT CARD REBATES - 2018 AMOUNT: $ 3,219. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 428529 167857 260672 39759 32424 7335 67429 37693 29736 297743 DEFERRED RENT 265611 265611 X 2104041 0 2104041 0 2104041 6300984 0 6300984 0 6300984 PART X, LINE 2: THE ORGANIZATION IS A NONPROFIT CORPORATION AS DESCRIBED IN SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND IS EXEMPT FROM FEDERAL AND STATE INCOME TAXES ON TRADE OR BUSINESS PROFITS GENERATED BY ACTIVITIES RELATED TO THE ORGANIZATION'S EXEMPT FUNCTION. THE ORGANIZATION MAY BE SUBJECT TO FEDERAL AND STATE INCOME TAXES FOR PROFITS GENERATED FROM TRADE OR BUSINESS ACTIVITIES UNRELATED TO THE ORGANIZATION'S EXEMPT FUNCTION. AS OF DECEMBER 31, 2018, MANAGEMENT BELIEVES THAT THE ORGANIZATION HAS NOT GENERATED ANY UNRELATED BUSINESS TAXABLE INCOME. THE ORGANIZATION ASSESSES THE RECORDING OF UNCERTAIN TAX POSITIONS BY EVALUATING THE MINIMUM RECOGNITION THRESHOLD AND MEASUREMENT REQUIREMENTS A TAX POSITION MUST MEET BEFORE BEING RECOGNIZED AS A BENEFIT IN THE FINANCIAL STATEMENTS. THE ORGANIZATION'S POLICY IS TO RECOGNIZE INTEREST AND PENALTIES ACCRUED ON ANY UNCERTAIN TAX POSITIONS AS A COMPONENT OF INCOME TAX EXPENSE, IF ANY, IN ITS STATEMENTS OF ACTIVITIES. EFFECTIVE FOR THE YEAR ENDED DECEMBER 31, 2018, THE TAX CUTS AND JOBS ACT OF 2017 REQUIRES NONPROFIT ORGANIZATIONS TO REMIT TAXES ON QUALIFYING TRANSPORTATION FRINGE BENEFITS. DURING THE YEAR ENDED DECEMBER 31, 2018, THE ORGANIZATION HAS DETERMINED THAT TAXES ARE OWED ON QUALIFYING TRANSPORTATION FRINGE BENEFITS AND HAS ACCRUED TAXES IN THE AMOUNT OF $6,188, WHICH HAS BEEN INCLUDED IN ACCRUED EXPENSES ON THE ACCOMPANYING STATEMENTS OF FINANCIAL POSITION. X X X X 0 0 0 0 0 0 0 0 0 STEVEN D PEARSON PRESIDENT 456398 0 20000 0 0 0 29950 0 19043 0 525391 0 0 0 SARAH K EMOND TREASURER, SECRETARY, COO 194532 0 0 0 0 0 20758 0 15565 0 230855 0 0 0 DAN OLLENDORF CHIEF SCIENTIFIC OFFICER 159484 0 0 0 0 0 21731 0 15077 0 196292 0 0 0 DAVID RIND CHIEF MEDICAL OFFICER 234494 0 0 0 0 0 26242 0 20261 0 280997 0 0 0 DAVID WHITRAP VP OF COMM. & OUTREACH 191901 0 0 0 0 0 9000 0 20877 0 221778 0 0 0 RICHARD CHAPMAN DIR OF HEALTH ECONOMICS 201206 0 0 0 0 0 9744 0 2591 0 213541 0 0 0 WILLIAM DREITLEIN DIR OF PHARMACEUTICAL INTELLIGENCE 146614 0 0 0 0 0 6367 0 19376 0 172357 0 0 0 FORM 990, PART I, LINE 1: ICER IS AN INDEPENDENT, NON-PARTISAN, NON-PROFIT RESEARCH ORGANIZATION THAT OBJECTIVELY EVALUATES THE CLINICAL AND ECONOMIC VALUE OF PRESCRIPTION DRUGS, MEDICAL TESTS, AND OTHER HEALTH CARE INTERVENTIONS. ICER CONDUCTS RIGOROUS ANALYSES OF ALL CLINICAL DATA AND PUBLICLY CONVENES KEY STAKEHOLDERS INCLUDING PATIENTS, DOCTORS, LIFE SCIENCES COMPANIES, AND INSURERS TO TRANSLATE THIS EVIDENCE INTO POLICY DECISIONS THAT LEAD TO A MORE EFFECTIVE, EFFICIENT, AND JUST HEALTH SYSTEM. ICER'S EVIDENCE REPORTS INCLUDE A FULL ANALYSIS OF HOW WELL EACH NEW MEDICINE WORKS, THE ECONOMIC VALUE EACH TREATMENT REPRESENTS, AND OTHER SOCIETAL FACTORS THAT POLICYMAKERS MAY NEED TO CONSIDER. THE REPORTS ESTABLISH HOW EACH DRUG SHOULD BE PRICED TO APPROPRIATELY REFLECT IMPROVED PATIENT OUTCOMES, AND THIS "VALUE-BASED PRICE BENCHMARK' IS INCREASINGLY GUIDING NEGOTIATIONS BETWEEN PHARMACEUTICAL MANUFACTURERS AND US PAYER ORGANIZATIONS. ICER'S ULTIMATE GOAL IS TO HELP THE US HEALTH SYSTEM ACHIEVE FAIR DRUG PRICING AND FAIR PATIENT ACCESS, WHILE RETAINING FINANCIAL INCENTIVES FOR FUTURE INNOVATION. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS FIRST REVIEWED IN DETAIL BY THE ORGANIZATION'S SENIOR MANAGEMENT TEAM. A FULL COPY OF THE FORM 990 IS THEN PROVIDED TO THE ENTIRE BOARD OF DIRECTORS FOR REVIEW PRIOR TO ITS FILING. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION'S CODE OF BUSINESS CONDUCT AND ETHICS, WHICH INCLUDES A CONFLICT OF INTEREST POLICY, IS REVIEWED ON AN ANNUAL BASIS. ALL OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE REQUIRED TO COMPLETE AND SIGN THE CONFLICT OF INTEREST POLICY ANNUALLY. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION FOR THE OFFICERS OF THE ORGANIZATION IS REVIEWED AND APPROVED BY THE GOVERNING BOARD'S COMPENSATION COMMITTEE ON AN ANNUAL BASIS. IN DOING SO, THE COMPENSATION COMMITTEE REVIEWS COMPENSATION DATA FROM PEER ORGANIZATIONS. COMPENSATION OF ADDITIONAL KEY EMPLOYEES IS REVIEWED AND APPROVED BY THE OFFICERS OF THE ORGANIZATION. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CODE OF BUSINESS CONDUCT AND ETHICS, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G MARKETING AND COMMUNICATIONS: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 99,343. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 99,343. OTHER PROFESSIONAL SERVICES: PROGRAM SERVICE EXPENSES 101,154. MANAGEMENT AND GENERAL EXPENSES 22,897. FUNDRAISING EXPENSES 742. TOTAL EXPENSES 124,793. CONTRACTOR SERVICES: PROGRAM SERVICE EXPENSES 1,383,072. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,383,072. FORM 990, PART XII, LINE 2C: THE ORGANIZATION HAS A COMMITTEE THAT ASSUMES RESPONSIBILITY FOR OVERSIGHT FOR THE AUDIT OF ITS FINANCIAL STATEMENTS AND SELECTION OF AN INDEPENDENT ACCOUNTANT. THIS PROCESS HAS NOT CHANGED DURING THE YEAR.